Literature DB >> 23770788

Effect of allopurinol on oxidative stress and hypoxic adaptation response during surgical correction of tetralogy of fallot.

Fathema D Rachmat1, Jusuf Rachmat, Sudigdo Sastroasmoro, Septelia I Wanandi.   

Abstract

AIM: to analyze the role of allopurinol in reducing the ischemia-reperfusion injury, and to confirm the HIF-1 binding activity changes during the surgical correction of tetralogy of fallot (TF).
METHODS: randomized, double-blind experimental study on patients undergoing surgical correction of TF in the Integrated Cardiovascular Services, Cipto Mangunkusumo Hospital from September 2009-May 2010. Patients were randomly divided into two groups. The first group was given 10 mg/kg body weight of allopurinol 3 times before undergoing operation (n=13) and the other group was given placebo (n=13). Tissue specimen from right ventricular muscle were taken for measurement of reactive oxygen species (ROS) expression and blood specimens from intra-coronary sinus for measurement of TNF-, superoxide dismutase (SOD), and malondialdehyde (MDA).
RESULTS: cardiomyocytes expressing ROS in placebo group increased (41.37±29.29%; 42.61±22.82% and 53.81±25.76%), while in allopurinol group decreased (44.68±19.79%, 56.87±15.50%, and 47.98±22.52%). Concentration of TNF- tend to decrease in allopurinol group, while it tended to increase in the placebo goup. Concentration of SOD increased in the allopurinol group, while in the placebo group there were no significant changes. Concentration of MDA was highly increased in the placebo group (1.75 pmol/mg; 2.37 pmol/mg; 2.72 pmol/mg; 4.82 pmol/mg), but statistically it was not significant. On the other hand, there was no significant change of MDA concentration in the allopurinol group. Expression of HIF-1 in TF patients decreased significantly (p=0.026) from pre ischemic phase to ischemic phase, but it increased in the reperfusion phase (0.95 OD/mg protein, 0.52 OD/mg protein, 0.9 OD/mg protein).
CONCLUSION: pre-surgical oral allopurinol treatment reduced ischemia-reperfusion injury during TF surgical correction, as indicated by the decrease in the number of cardiomyocytes expressing ROS, reducing TNF-, SOD, and MDA concentration in blood. There was a decrease in HIF-1 concentration in cardiomyocytes of the right ventricle during ischemic phase.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770788

Source DB:  PubMed          Journal:  Acta Med Indones        ISSN: 0125-9326


  6 in total

1.  Ameliorative effect of allopurinol on vascular complications of insulin resistance.

Authors:  Hany M El-Bassossy; Ahmed A Elberry; Ahmad Azhar; Salah A Ghareib; Abdulrahman M Alahdal
Journal:  J Diabetes Res       Date:  2015-02-15       Impact factor: 4.011

2.  Curcumin attenuates hypoxia/reoxygenation‑induced myocardial injury.

Authors:  Wenjuan Wei; Jun Peng; Jian Li
Journal:  Mol Med Rep       Date:  2019-10-15       Impact factor: 2.952

3.  Allopurinol Protects against Ischemia/Reperfusion-Induced Injury in Rat Urinary Bladders.

Authors:  Ju-Hyun Shin; Kwang Sik Chun; Yong-Gil Na; Ki-Hak Song; Seung Il Kim; Jae-Sung Lim; Gun-Hwa Kim
Journal:  Oxid Med Cell Longev       Date:  2015-09-27       Impact factor: 6.543

4.  Effect of amlodipine, lisinopril and allopurinol on acetaminophen-induced hepatotoxicity in rats.

Authors:  Nesreen E M Mohammed; Basim A S Messiha; Ali A Abo-Saif
Journal:  Saudi Pharm J       Date:  2015-05-19       Impact factor: 4.330

Review 5.  Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress.

Authors:  Jorge G Farías; Víctor M Molina; Rodrigo A Carrasco; Andrea B Zepeda; Elías Figueroa; Pablo Letelier; Rodrigo L Castillo
Journal:  Nutrients       Date:  2017-09-01       Impact factor: 5.717

6.  Ginkgetin Alleviates Inflammation, Oxidative Stress, and Apoptosis Induced by Hypoxia/Reoxygenation in H9C2 Cells via Caspase-3 Dependent Pathway.

Authors:  Xin Liu; Hong Bian; Qing-Li Dou; Xian-Wen Huang; Wu-Yuan Tao; Wen-Hua Liu; Na Li; Wen-Wu Zhang
Journal:  Biomed Res Int       Date:  2020-11-04       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.